Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer
- 30 April 1997
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 23 (2) , 151-156
- https://doi.org/10.1016/s0748-7983(97)80011-x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Tumour Markers CA 19-9 and CA 50 in Digestive Tract MalignanciesScandinavian Journal of Gastroenterology, 1992
- Comparative Study of CA-50 (Time-Resolved Fluoroimmunoassay), Span-1, and CA19-9 in the Diagnosis of Pancreatic CancerScandinavian Journal of Gastroenterology, 1991
- Working Group on Tumor Marker Criteria (WGTMC)Tumor Biology, 1990
- A Clinical Evaluation of Monoclonal (CA19-9, CA50, CA 12-5) and Polyclonal (CEA, TPA) Antibody-Defined Antigens for the Diagnosis of Pancreatic CancerPancreas, 1988
- CA-50 in patients with pancreatic disease—an evaluation of three different laboratory techniquesScandinavian Journal of Clinical and Laboratory Investigation, 1988
- Serum ca 50 as a tumor marker in pancreatic cancer: A comparison with CA 19‐9International Journal of Cancer, 1987
- The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic diseaseBritish Journal of Cancer, 1986
- Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibodyFEBS Letters, 1985
- Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinomaBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1985
- Colorectal carcinoma antigens detected by hybridoma antibodiesSomatic Cell and Molecular Genetics, 1979